91.30
-2.14%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biomerieux
Its shares trade on Euronext Paris under the ticker BIM.PA. It has been listed since 7 June 2004. In the fiscal year to 31 December 2025, it reported revenue of €4.07bn and net income of €397.5m. At that date it held total assets of €5.57bn and shareholders' equity of €4.10bn.
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Marcy-L Etoile, Auvergne-Rhone-Alpes. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 7 Jun 2004
- Employees
- 11,795
- Website
- biomerieux.fr ↗
Leadership
Pay as last reported
- Mr. Alexandre MerieuxChairman of the Board€1.7m
- Mr. Pierre BouludChief Executive Officer, Member of the Executive Board€1.4m
- Mr. Guillaume BouhoursChief Financial Officer, Executive Vice President - Purchasing and Information Systems, Member of the Executive Committee
- Mr. Audrey DauvetExecutive Vice President - Legal Corporate Integrity and Public Affairs, General Counsel, Member of the Executive Committee
- Ms. Valerie LeyldeExecutive Vice President - Human Resources, Communication and CSR, Member of the Executive Committee, since 2022
- Dr. Pierre CharbonnierExecutive Vice President - Global Quality, Manufacturing and Supply Chain, Member of the Executive Committee
- Dr. Charles CooperExecutive Vice President, Chief Medical Officer, Member of the Executive Committee
- Mr. Yasha MitrottiExecutive Vice President - Industrial Applications, Member of the Executive Committee, since 2024
- Ms. Jennifer ZinnExecutive Vice President - Clinical Operations, Member of the Executive Committee
- Ms. Celine Roger-DalbertExecutive Director - Research and Development, Member of the Executive Committee
- Dr. Philippe ArchinardNon-Independent Director€46,833
- Mr. Jean-Luc BelingardNon-Independent Director, since 2006€37,833
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 99
- Social
- 99
- Governance
- 56
- Direct emissions (scope 1)
- 22,000 t
- Energy emissions (scope 2)
- 40,000 t
- Value chain emissions (scope 3)
- 1,127,000 t
- Women in the workforce
- 49%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biomerieux SA holds several notable strengths that contribute to its success within the industry. 1. Advanced Technology: Biomerieux SA utilizes cutting-edge technology and innovative solutions, allowing it to stay ahead of the competition. 2. Established Global Presence: With operations in numerous countries, Biomerieux SA has a strong global footprint, enabling it to serve a diverse customer base. 3. Extensive Product Portfolio: The company offers a wide range of products and services, catering to various segments of the healthcare and diagnostics market. 4. Strong Research and Development: Biomerieux SA invests significantly in research and development, fostering continuous improvement and the development of new products and solutions.
Weaknesses
- Despite its strengths, Biomerieux SA also faces certain weaknesses that pose challenges for the organization. 1. Dependence on External Suppliers: Biomerieux SA relies on external suppliers for certain key components, which may lead to potential supply chain disruptions. 2. High R&D Costs: While strong research and development activities drive innovation, they also result in high costs, which may impact the company's profitability. 3. Limited Product Differentiation: In a competitive market, some of Biomerieux SA's products may lack significant differentiation from those offered by its competitors, potentially impacting market share.
Opportunities
- Biomerieux SA can leverage various opportunities to further enhance its business and market position. 1. Increasing Demand for Diagnostics: The global demand for diagnostics is growing, providing an opportunity for Biomerieux SA to expand its customer base and revenue streams. 2. Rising Healthcare Expenditure: As healthcare expenditure continues to rise worldwide, Biomerieux SA can benefit from increased spending on medical equipment and diagnostics. 3. Expansion into Emerging Markets: Entry into untapped emerging markets can open new avenues for Biomerieux SA, allowing it to establish a stronger global presence and diversify its revenue sources.
Threats
- Biomerieux SA faces certain threats that may hinder its growth and stability. 1. Intense Competition: The healthcare and diagnostics industry is highly competitive, with numerous companies vying for market share, which may impact Biomerieux SA's position. 2. Regulatory Challenges: Compliance with stringent regulations in different regions can pose challenges to Biomerieux SA's operations and product approvals. 3. Economic Volatility: Economic uncertainties and fluctuations in exchange rates could adversely affect Biomerieux SA's financial performance and international business operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.